Newsroom

Takeda’s TAKHZYRO^® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO^® (lanadelumab-flyo) for Use as a Preventive Treatment for Hereditary Angioedema Attacks

FDA Approves Prophylactic Treatment with VONVENDI^® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)

Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721

Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021